CLINICAL TRIAL

Safety and Efficacy Study of Sirolimus 
in Complicated Vascular Anomalies

An FDA funded Phase 2 Study – Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular Anomalies is being sponsored by Cincinnati Children’s Hospital Medical Center. The ClinicalTrials.gov identifier for this study is NCT00975819.  Eligibility of conditions - including lymphatic malformations (lymphangiomatosis) may be reviewed in the description of the Phase 2 Clinical Trial.

Those interested in further information about the study please visit: http://clinicaltrials.gov/     Enter in the search bar “Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies”. There, you can find detailed information about the study including a detailed description, eligibility requirements, research location, and full contact information.  The primary study contacts are Matthew B. Allen, Clinical Research Coordinator and Mary Sue Wentzel, RN.    Principal Investigator is Denise M. Adams, MD, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio.

Cincinnati Children’s Hospital Medical Center has a Hemangioma and Vascular Malformations Center (HVMC) which has treated and/or consulted in cases of patients with lymphangiomatosis & Gorham’s disease.